Atara Biotherapeutics (ATRA) Net Equity Issued and Repurchased (2013 - 2026)
Atara Biotherapeutics (ATRA) posted Net Equity Issued and Repurchased of $3.0 million for Q1 2026, up 11904.0% on a QoQ basis from -$25000.0 in Q4 2025.
Atara Biotherapeutics (ATRA) Net Equity Issued and Repurchased (2013 - 2026) Analysis & Trends
Atara Biotherapeutics' Net Equity Issued and Repurchased history runs 13 years deep, the most recent figure standing at $3.0 million for Q1 2026.
- Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 million (up 17107.69% YoY) and the FY2025 annual result came in at $1.5 million, down 84.26% from the prior year.
- Net Equity Issued and Repurchased was $3.0 million for Q1 2026 at Atara Biotherapeutics, up from -$25000.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $20.5 million in Q1 2022 and bottomed at -$50000.0 in Q2 2023.
- A 5-year average of $3.4 million and a median of $1.4 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2023 — Net Equity Issued and Repurchased slumped 117.39% — and 2024, when it jumped 1364.69%.
- Atara Biotherapeutics' Net Equity Issued and Repurchased stood at $1.4 million in 2022, then grew by 12.44% to $1.5 million in 2023, then sank by 101.68% to -$26000.0 in 2024, then grew by 3.85% to -$25000.0 in 2025, then jumped by 11904.0% to $3.0 million in 2026.
- Business Quant data shows ATRA's Net Equity Issued and Repurchased at $3.0 million in Q1 2026, -$25000.0 in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 141.90 Mn |
| 10 | Atara Biotherapeutics | 110.04 Mn | 101.68 Mn | 392,000.00 | 2.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.95 Mn |
| Mar 31, 2026 | 2.95 Mn |
| Dec 31, 2025 | -25,000.00 |
| Dec 31, 2025 | -25,000.00 |
| Sep 30, 2025 | 1.50 Mn |
| Sep 30, 2025 | 1.50 Mn |
| Jun 30, 2024 | -26,000.00 |
| Jun 30, 2024 | -26,000.00 |
| Mar 31, 2024 | 9.37 Mn |
| Mar 31, 2024 | 9.37 Mn |
| Dec 31, 2023 | 1.55 Mn |
| Dec 31, 2023 | 1.55 Mn |
| Jun 30, 2023 | -50,000.00 |
| Jun 30, 2023 | -50,000.00 |
| Mar 31, 2023 | 640,000.00 |
| Mar 31, 2023 | 640,000.00 |
| Dec 31, 2022 | 1.38 Mn |
| Dec 31, 2022 | 1.38 Mn |
| Jun 30, 2022 | -23,000.00 |
| Jun 30, 2022 | -23,000.00 |